Recently, Hsieh et al. [18] applied the combined RNA-Seq and Ribo-Seq approach to prostate cancer cells treated with two mTOR inhibitors: rapamycin, which is an allosteric mTOR inhibitor, and PP242, which is a more potent inhibitor that interferes with mTOR's ATP site. Here, MTOR is linked to prostate carcinoma.